Minh Phú Seafood Corporation has just sent an official dispatch to the People Committee of Cà Mau asking for support for the Nanocovax vaccine trial injection.
On 1st August, Lê Văn Quang, Chairman of Minh Phu Seafood Corporation, signed an official letter to the People Committee of Cà Mau and Department of Health of this province, asking for support for the Nanocovax vaccine trial injection.
Mr. Quang said that Minh Phú Seafood Corporation was a company working in shrimp breeding – farming – processing – export with a chain of 15 member companies and many other affiliates and partners.
Currently, the personnel network of this corporation is widely distributed from Hà Nội, Ninh Thuận, Bà Rịa – Vũng Tàu, HCMC, Đồng Nai, Bình Dương, Hậu Giang, Kiên Giang, Sóc Trăng, Cà Mau and Mekong Delta provinces.
Minh Phu Seafood Corporation has proposed the People Committee of Cà Mau and Department of Health of this province to allow the company to register for the Nanocovax vaccine trial inoculation, which was studied and developed by Nanogen Pharmaceutical Biotechnology Joint Stock Company, in order to protect and take care of employees’ health, maintain the supply chain, as well as encourage the domestic vaccination research, production and usage. This vaccine is supposed to inoculate 200.000 employees, including company staff, shrimp-farming households, purchasing agents, partners and the relatives of those mentioned working in Cà Mau province.
The corporation committed to actively promote this vaccine to create high consensus, prepare necessary conditions and use the supplied vaccines in a safe, effective and legal assurance.
The Nanocovax vaccine was developed by Nanogen Pharmaceutical Biotechnology Joint Stock Company. The result of the 3rd trial phase is expected to be completed from 4th August 2021 to 19th August 2021. The Ministry of Health has ordered and assigned a group of domestic experts and WHO experts to support for the producers and researchers (Pasteur Institute in Ho Chi Minh City – Military Medical Academy) in order to accomplish research profiles, primarily evaluate immunogenicity test results, and accomplish report and registration documents, whose submissions would be evaluated by several boards (expected to take place from 15 to 20th August 2021).
Formerly, Nanogen Company has well implemented the Nanocovax vaccine trial with about 14.000 people who were vaccinated in the 3rd phase, and there were no case of severe reactions but a mild fever.
Gia Nguyên
Source: Trọng Linh, Nông nghiệp Việt Nam via Tép Bạc
